Knutson D D, Swinyer L J, Smoot W H
Cutis. 1981 Feb;27(2):203-4, 208-10.
Meclocycline sulfosalicylate is a broad spectrum antimicrobial agent that was synthesized in 1960 and has been marketed abroad for several years. Clinical studies in the United States to date involve 351 patients. The results of a regimen using topically applied meclocycline sulfosalicylate, 1 percent, as the sole treatment are examined. Overall 82 percent of the patients treated with the active preparation experienced clinical improvement in a twice daily application regimen. Excellent of good results were obtained in 62.3 percent of patients treated with meclocycline sulfosalicylate cream as compared with 27.5 percent of those treated with the cream vehicle alone. The median percent reduction in the number of inflammatory lesions of acne among patients treated for 11 weeks was 57.1 percent. Rapid response was noted at week 5, with nearly a 50 percent median reduction in papules and pustules. The low incidence of local adverse effects was noteworthy. Only one case of contact dermatitis possibly related to treatment was reported among the patients studied.
磺基水杨酸甲氯环素是一种广谱抗菌剂，于1960年合成，已在国外上市数年。美国迄今为止的临床研究涉及351名患者。对使用1%磺基水杨酸甲氯环素局部应用作为唯一治疗方案的结果进行了研究。总体而言，在每日两次的应用方案中，使用活性制剂治疗的患者中有82%临床症状得到改善。使用磺基水杨酸甲氯环素乳膏治疗的患者中，62.3%取得了优异或良好的效果，而仅使用乳膏赋形剂治疗的患者中这一比例为27.5%。接受治疗11周的痤疮患者炎症性皮损数量减少的中位数百分比为57.1%。在第5周时观察到快速反应，丘疹和脓疱数量减少的中位数接近50%。局部不良反应的发生率较低，值得注意。在研究的患者中，仅报告了1例可能与治疗有关的接触性皮炎病例。
